FDA Approves One Drug for Three Rare Cancer Subtypes

The  U.S. Food and Drug Administration (FDA) has approved the kinase inhibitor, Retevmo (selpercatinib), to treat people with three cancers that have a mutation or fusion in the RET gene. The three cancers are:  Non-small cell lung cancer (NSCLC) that has spread...